Inhibition of G-protein-coupled receptor kinase 2 prevents the dysfunctional cardiac substrate metabolism in fatty acid synthase transgenic mice

Journal of Biological Chemistry

Volumn 291, Issue 6, 2016, Pages 2583-2600

  Alla, Joshua Abd ^a   Graemer, Muriel ^a   Fu, Xuebin ^a,b   Quitterer, Ursula ^a,c  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CARDIOLOGY; CYTOLOGY; ENZYMES; GENE EXPRESSION; HEART; MAMMALS; METABOLISM; PALMITIC ACID; PHYSIOLOGY; PLANTS (BOTANY); PROTEINS;

FATTY ACID SYNTHASE; G PROTEIN-COUPLED RECEPTOR KINASE 2; KINASE INHIBITORS; PEPTIDE INHIBITORS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; SUBSTRATE UTILIZATION; TRANSGENIC EXPRESSION; TRANSGENIC MODELS;

FATTY ACIDS;

FATTY ACID SYNTHASE; G PROTEIN COUPLED RECEPTOR KINASE 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; UNCOUPLING PROTEIN 1; ADRBK1 PROTEIN, MOUSE; RAF KINASE INHIBITORY PROTEIN, MOUSE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DOWN REGULATION; ENERGY TRANSFER; ENZYME INHIBITION; ENZYME SPECIFICITY; FATTY ACID METABOLISM; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE METABOLISM; HEART PROTECTION; HEART VENTRICLE OVERLOAD; LIPID METABOLISM; LIPOTOXICITY; MALE; MOUSE; NEWBORN; NONHUMAN; OXIDATIVE PHOSPHORYLATION UNCOUPLING; PHENOTYPE; PPARG GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSGENIC MOUSE; UPREGULATION; ANIMAL; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; FATTY ACID SYNTHASE, TYPE I; G-PROTEIN-COUPLED RECEPTOR KINASE 2; HEART FAILURE; MICE; MICE, TRANSGENIC; MYOCARDIUM; MYOCYTES, CARDIAC; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PPAR GAMMA;

EID: 84958213949     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.702688     Document Type: Article

References (59)

1. Nakou, E. S., and Vardas, P. E. (2013) New therapeutic options in heart failure. What's on the horizon? An overview. Int. J. Cardiol. 170, 95-106.
2. Bui, A. L., Horwich, T. B., and Fonarow, G. C. (2011) Epidemiology and risk profile of heart failure. Nat. Rev. Cardiol. 8, 30-41.
3. Taegtmeyer, H., and Stanley, W. C. (2011) Too much or not enough of a good thing? Cardiac glucolipotoxicity versus lipoprotection. J. Mol. Cell. Cardiol. 50, 2-5.
4. Wittels, B., and Spann, J. F. (1968) Defective lipid metabolism in the failing heart. J. Clin. Invest. 47, 1787-1794.
5. Bishop, S. P., and Altschuld, R. A. (1970) Increased glycolytic metabolism in cardiac hypertrophy and congestive failure. Am. J. Physiol. 218, 153-159.
6. Stanley, W. C., Recchia, F. A., and Lopaschuk, G. D. (2005) Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 85, 1093-1129.
7. Berthiaume, J. M., Bray, M. S., McElfresh, T. A., Chen, X., Azam, S., Young, M. E., Hoit, B. D., and Chandler, M. P. (2010) The myocardial contractile response to physiological stress improves with high saturated fat feeding in heart failure. Am. J. Physiol. Heart Circ. Physiol. 299, H410-H421.
8. Lahey, R., Wang, X., Carley, A. N., and Lewandowski, E. D. (2014) Dietary fat supply to failing hearts determines dynamic lipid signaling for nuclear receptor activation and oxidation of stored triglyceride. Circulation 130, 1790-1799.
9. Neubauer, S. (2007) The failing heart-an engine out of fuel. N. Engl. J. Med. 356, 1140-1151.
10. Razani, B., Zhang, H., Schulze, P. C., Schilling, J. D., Verbsky, J., Lodhi, I. J., Topkara, V. K., Feng, C., Coleman, T., Kovacs, A., Kelly, D. P., Saffitz, J. E., Dorn, G. W.2nd., Nichols, C. G., and Semenkovich, C. F. (2011) Fatty acid synthase modulates homeostatic responses to myocardial stress. J. Biol. Chem. 286, 30949-30961.
11. Abdalla, S., Fu, X., Elzahwy, S. S., Klaetschke, K., Streichert, T., and Quitterer, U. (2011) Up-regulation of the cardiac lipid metabolism at the onset of heart failure. Cardiovasc. Hematol. Agents Med. Chem. 9, 190-206.
12. Fu, X., Koller, S., Abd Alla, J., and Quitterer, U. (2013) Inhibition of G-protein- coupled receptor kinase 2 (GRK2) triggers the mitogen-activated protein kinase (MAPK) pathway. J. Biol. Chem. 288, 7738-7755.
13. Lucas, E., Jurado-Pueyo, M., Fortuño, M. A., Fernández-Veledo, S., Vila- Bedmar, R., Jiménez-Borreguero, L. J., Lazcano, J. J., Gao, E., Gómez- Ambrosi, J., Frühbeck, G., Koch, W. J., Díez, J., Mayor, F. Jr., and Murga, C. (2014) Downregulation of G protein-coupled receptor kinase 2 levels enhances cardiac insulin sensitivity and switches on cardioprotective gene expression patterns. Biochim. Biophys. Acta 1842, 2448-2456.
14. Wang, Y., Gao, E., Lau, W. B., Wang, Y., Liu, G., Li, J. J., Wang, X., Yuan, Y., Koch, W. J., and Ma, X. L. (2015) G-protein-coupled receptor kinase 2-mediated desensitization of adiponectin receptor in failing heart. Circulation 131, 1392-1404.
15. Chou, I. P., Lin, Y. Y., Ding, S. T., and Chen, C. Y. (2014) Adiponectin receptor 1 enhances fatty acid metabolism and cell survival in palmitatetreated HepG2 cells through the PI3K/AKT pathway. Eur. J. Nutr. 53, 907-917.
16. Kim, J. E., Ahn, M. W., Baek, S. H., Lee, I. K., Kim, Y. W., Kim, J. Y., Dan, J. M., and Park, S. Y. (2008) AMPK activator, AICAR, inhibits palmitateinduced apoptosis in osteoblast. Bone 43, 394-404.
17. Quitterer, U., Pohl, A., Langer, A., Koller, S., and Abdalla, S. (2011) A cleavable signal peptide enhances cell surface delivery and heterodimerization of Cerulean-tagged angiotensin II AT1 and bradykinin B2 receptor. Biochem. Biophys. Res. Commun. 409, 544-549.
18. Abd Alla, J., El Faramawy, Y., and Quitterer, U. (2013) Microarray gene expression profiling reveals antioxidant-like effects of angiotensin II inhibition in atherosclerosis. Front. Physiol. 4, 148.
19. Abd Alla, J., Pohl, A., Reeck, K., Streichert, T., and Quitterer, U. (2010) Establishment of an in vivo model facilitates B2 receptor protein maturation and heterodimerization. Integr. Biol. 2, 209-217.
20. AbdAlla, S., Lother, H., el Missiry, A., Langer, A., Sergeev, P., el Faramawy, Y., and Quitterer, U. (2009) Angiotensin II AT2 receptor oligomers mediate G-protein dysfunction in an animal model of Alzheimer disease. J. Biol. Chem. 284, 6554-6565.
21. Lorenz, K., Lohse, M. J., and Quitterer, U. (2003) Protein kinaseCswitches the Raf kinase inhibitor from Raf-1 to GRK2. Nature 426, 574-579.
22. Liu, L., Trent, C. M., Fang, X., Son, N. H., Jiang, H., Blaner, W. S., Hu, Y., Yin, Y. X., Farese, R. V.Jr., Homma, S., Turnbull, A. V., Eriksson, J. W., Hu, S. L., Ginsberg, H. N., Huang, L. S., and Goldberg, I. J. (2014) Cardiomyocyte- specific loss of diacylglycerol acyltransferase 1 (DGAT1) reproduces the abnormalities in lipids found in severe heart failure. J. Biol. Chem. 289, 29881-29891.
23. Kim, C., Wong, J., Wen, J., Wang, S., Wang, C., Spiering, S., Kan, N. G., Forcales, S., Puri, P. L., Leone, T. C., Marine, J. E., Calkins, H., Kelly, D. P., Judge, D. P., and Chen, H. S. (2013) Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature 494, 105-110.
24. Biagi, P. L., Bordoni, A., Lorenzini, A., Horrobin, D. F., and Hrelia, S. (1999) Essential fatty acid metabolism in long term primary cultures of rat cardiomyocytes: A beneficial effect of n-6:n-3 fatty acids supplementation. Mech. Ageing Dev. 107, 181-195.
25. Lopaschuk, G. D., and Jaswal, J. S. (2010) Energy metabolic phenotype of the cardiomyocyte during development, differentiation, and postnatal maturation. J. Cardiovasc. Pharmacol. 56, 130-140.
26. Park, T. S., and Goldberg, I. J. (2012) Sphingolipids, lipotoxic cardiomyopathy, and cardiac failure. Heart Fail. Clin. 8, 633-641.
27. Mochly-Rosen, D., Das, K., and Grimes, K. V. (2012) Protein kinase C, an elusive therapeutic target? Nat. Rev. Drug Discov. 11, 937-957.
28. Liu, Q., and Molkentin, J. D. (2011) Protein kinase C- As a heart failure therapeutic target. J. Mol. Cell. Cardiol. 51, 474-478.
29. Son, N. H., Yu, S., Tuinei, J., Arai, K., Hamai, H., Homma, S., Shulman, G. I., Abel, E. D., and Goldberg, I. J. (2010) PPAR-induced cardiolipotoxicity in mice is ameliorated by PPAR- deficiency despite increases in fatty acid oxidation. J. Clin. Invest. 120, 3443-3454.
30. Graham, D. J., Ouellet-Hellstrom, R., MaCurdy, T. E., Ali, F., Sholley, C., Worrall, C., and Kelman, J. A. (2010) Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304, 411-418.
31. Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M., and Lehmann, J. M. (1997) Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors a and ß. Proc. Natl. Acad. Sci. U.S.A. 94, 4318-4323.
32. Hamza, M. S., Pott, S., Vega, V. B., Thomsen, J. S., Kandhadayar, G. S., Ng, P. W., Chiu, K. P., Pettersson, S., Wei, C. L., Ruan, Y., and Liu, E. T. (2009) De novo identification of PPAR-/RXR binding sites and direct targets during adipogenesis. PLoS ONE 4, e4907.
33. Chirala, S. S., Chang, H., Matzuk, M., Abu-Elheiga, L., Mao, J., Mahon, K., Finegold, M., and Wakil, S. J. (2003) Fatty acid synthesis is essential in embryonic development: fatty acid synthase null mutants and most of the heterozygotes die in utero. Proc. Natl. Acad. Sci. U.S.A. 100, 6358-6363.
34. Knobloch, M., Braun, S. M., Zurkirchen, L., von Schoultz, C., Zamboni, N., Araúzo-Bravo, M. J., Kovacs, W. J., Karalay, O., Suter, U., Machado, R. A., Roccio, M., Lutolf, M. P., Semenkovich, C. F., and Jessberger, S. (2013) Metabolic control of adult neural stem cell activity by Fasn-dependent lipogenesis. Nature 493, 226-230.
35. Brinks, H., and Koch, W. J. (2010) Targeting G protein-coupled receptor kinases (GRKs) in heart failure. Drug Discov. Today Dis. Mech. 7, e129-e134.
36. Banks, A. S., McAllister, F. E., Camporez, J. P., Zushin, P. J., Jurczak, M. J., Laznik-Bogoslavski, D., Shulman, G. I., Gygi, S. P., and Spiegelman, B. M. (2015) An ERK/Cdk5 axis controls the diabetogenic actions of PPARG. Nature 517, 391-395.
37. Ungerer, M., Böhm, M., Elce, J. S., Erdmann, E., and Lohse, M. J. (1993) Altered expression of ß-adrenergic receptor kinase and -1-adrenergic receptors in the failing human heart. Circulation 87, 454-463.
38. Piguet, A. C., Stroka, D., Zimmermann, A., and Dufour, J. F. (2010) Hypoxia aggravates non-alcoholic steatohepatitis in mice lacking hepatocellular PTEN. Clin. Sci. 118, 401-410.
39. Lee, H. J., Ryu, J. M., Jung, Y. H., Oh, S. Y., Lee, S. J., and Han, H. J. (2015) Novel pathway for hypoxia-induced proliferation and migration in human mesenchymal stem cells: involvement of HIF-1-, FASN and mTORC1. Stem Cells 33, 2182-2195.
40. Choi, J. H., Banks, A. S., Estall, J. L., Kajimura, S., Boström, P., Laznik, D., Ruas, J. L., Chalmers, M. J., Kamenecka, T. M., Blüher, M., Griffin, P. R., and Spiegelman, B. M. (2010) Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPAR- by Cdk5. Nature 466, 451-456.
41. Zheng, H., Worrall, C., Shen, H., Issad, T., Seregard, S., Girnita, A., and Girnita, L. (2012) Selective recruitment of G protein-coupled receptor kinases (GRKs) controls signaling of the insulin-like growth factor 1 receptor. Proc. Natl. Acad. Sci. U.S.A. 109, 7055-7060.
42. Lips, D. J., Bueno, O. F., Wilkins, B. J., Purcell, N. H., Kaiser, R. A., Lorenz, J. N., Voisin, L., Saba-El-Leil, M. K., Meloche, S., Pouysségur, J., Pagès, G., De Windt, L. J., Doevendans, P. A., and Molkentin, J. D. (2004) MEK-ERK2 signaling pathways protects myocardium from ischemic injury in vivo. Circulation 109, 1938-1941.
43. Hu, E., Kim, J. B., Sarraf, P., and Spiegelman, B. M. (1996) Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPAR-. Science 274, 2100-2103.
44. Dadson, K., Turdi, S., Hashemi, S., Zhao, J., Polidovitch, N., Beca, S., Backx, P. H., McDermott, J. C., and Sweeney, G. (2015) Adiponectin is required for cardiac MEF2 activation during pressure overload-induced hypertrophy. J. Mol. Cell. Cardiol. 86, 102-109.
45. Chemaly, E. R., Hadri, L., Zhang, S., Kim, M., Kohlbrenner, E., Sheng, J., Liang, L., Chen, J., K-Raman, P., Hajjar, R. J., and Lebeche, D. (2011) Longterm in vivo resistin overexpression induced myocardial dysfunction and remodeling in rats. J. Mol. Cell. Cardiol. 51, 144-155.
46. Liu, C., Feng, T., Zhu, N., Liu, P., Han, X., Chen, M., Wang, X., Li, N., Li, Y., Xu, Y., and Si, S. (2015) Identification of a novel selective agonist of PPARG with no promotion of adipogenesis and less inhibition of osteoblastogenesis. Sci. Rep. 5, 9530.
47. Murholm, M., Dixen, K., and Hansen, J. B. (2010) Ras signaling regulates differentiation and UCP1 expression in models of brown adipogenesis. Biochim. Biophys. Acta 1800, 619-627.
48. Joseph, J. W., Koshkin, V., Saleh, M. C., Sivitz, W. I., Zhang, C. Y., Lowell, B. B., Chan, C. B., and Wheeler, M. B. (2004) Free fatty acid-induced beta-cell defects are dependent on uncoupling protein 2 expression. J. Biol. Chem. 279, 51049-51056.
49. Li, N., Wang, J., Gao, F., Tian, Y., Song, R., and Zhu, S. J. (2010) The role of uncoupling protein 2 in the apoptosis induced by free fatty acid in rat cardiomyocytes. J. Cardiovasc. Pharmacol. 55, 161-167.
50. Bodyak, N., Rigor, D. L., Chen, Y. S., Han, Y., Bisping, E., Pu, W. T., and Kang, P. M. (2007) Uncoupling protein 2 modulates cell viability in adult rat cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 293, H829-H835.
51. George, J., Patal, S., Wexler, D., Sharabi, Y., Peleg, E., Kamari, Y., Grossman, E., Sheps, D., Keren, G., and Roth, A. (2006) Circulating adiponectin concentrations in patients with congestive heart failure. Heart 92, 1420-1424.
52. O'Shea, K. M., Chess, D. J., Khairallah, R. J., Rastogi, S., Hecker, P. A., Sabbah, H. N., Walsh, K., and Stanley, W. C. (2010) Effects of adiponectin deficiency on structural and metabolic remodeling in mice subjected to pressure overload. Am. J. Physiol. Heart Circ. Physiol. 298, H1639-H1645.
53. Frankel, D. S., Vasan, R. S., D'Agostino, R. B. Sr., Benjamin, E. J., Levy, D., Wang, T. J., and Meigs, J. B. (2009) Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J. Am. Coll. Cardiol. 53, 754-762.
54. Chatham, J. C., and Young, M. E. (2012) Metabolic remodeling in the hypertrophic heart: fuel for thought. Circ. Res. 111, 666-668.
55. Kujiraoka, T., Satoh, Y., Ayaori, M., Shiraishi, Y., Arai-Nakaya, Y., Hakuno, D., Yada, H., Kuwada, N., Endo, S., Isoda, K., and Adachi, T. (2013) Hepatic extracellular signal-regulated kinase 2 suppresses endoplasmic reticulum stress and protects from oxidative stress and endothelial dysfunction. J. Am. Heart Assoc. 2, e000361.
56. Marfella, R., Di Filippo, C., Portoghese, M., Barbieri, M., Ferraraccio, F., Siniscalchi, M., Cacciapuoti, F., Rossi, F., D'Amico, M., Paolisso, G. (2009) Myocardial lipid accumulation in patients with pressure-overloaded heart and metabolic syndrome. J. Lipid Res. 50, 2314-2323.
57. Hansmann, G., Wagner, R. A., Schellong, S., Perez, V. A., Urashima, T., Wang, L., Sheikh, A. Y., Suen, R. S., Stewart, D. J., and Rabinovitch, M. (2007) Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor ?- Activation. Circulation 115, 1275-1284.
58. Woodall, M. C., Ciccarelli, M., Woodall, B. P., and Koch, W. J. (2014) G protein-coupled receptor kinase 2: A link between myocardial contractile function and cardiac metabolism. Circ. Res. 114, 1661-1670.
59. Dy, G. K., and Adjei, A. A. (2013) Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J. Clin. 63, 249-279.